Three drugs were compared for their efficacy in treating murine transitional cell carcinoma (TCC) of the bladder. Intravesical gene therapy treatments utilizing expression-targeted plasmids, where the murine cyclooxygenase-2 (Cox-2) promoter was used to drive the expression of exogenously inducible forms of caspases 3 and 9, were compared with treatment modalities employing Bacille Calmette-Guérin (BCG) and celecoxib. When administered via lavage, only the gene therapy regimen was found to be effective at restricting tumor progression following a 7-day incubation of tumor tissues. Celecoxib was also administered via the diet to allow for systemic delivery of the drug. The most efficacious celecoxib use tested yielded tumors with masses of (18.3 ± 8.4 mg) versus the gene delivery method, which yielded tumors with masses of (3.6±7.7 mg). The difference was significant (t-test, nX4, Po0.025). The results showed that the Cox-2 expression-targeted gene therapy system could efficiently bypass the bladder permeability barrier and more effectively inhibit tumor growth and development than either BCG or celecoxib treatments. Long-term data further demonstrated that the gene therapy system could effectively inhibit tumor growth and elongate life expectancy.
Introduction
The current gold standard for first-line immunotherapeutic in situ treatment of transitional cell carcinoma is Bacille Calmette-Gue´rin (BCG). 1 BCG is prepared from Mycobacterium bovis, an attenuated live bovine tuberculosis bacillus that is used as a vaccine against tuberculosis. In 1929, Pearl 2 first suggested BCG as a drug for cancer therapy when he noticed that patients with tuberculosis had a lower frequency of cancer, but it was not until the 1960s that BCG was used as a component of cancer therapy. Intravesical BCG administration has since been established as an effective immunotherapy for superficial transitional cell carcinomas. 1, 3 Another drug, celecoxib (marketed by Pfizer, New York, NY under the brand name Celebrex), has also been extensively studied as a chemopreventive agent for various cancer types such as colon, [4] [5] [6] lung, [7] [8] [9] breast, [10] [11] [12] prostate, 13,14 gastric 15 and bladder cancers. 16, 17 Celecoxib, approved for clinical use by the US Food and Drug Administration in 1998, was first developed as a potential treatment for rheumatoid arthritis and osteoarthritis. 18 Celexocib specifically inhibits cyclooxygenase-2 (Cox-2), and therefore has fewer side effects than other non-steroidal anti-inflammatory drugs such as aspirin and ibuprofen, which inhibit both Cox-1 and -2. The exact mechanism of the chemopreventive effects of celecoxib remains unclear. Some attribute the effects to the inhibition of Cox-2, which results in a decrease in prostaglandin production. 5, 16, 17 However, cellular Cox-2 expression does not always correlate with cellular response to celecoxib, which implies that the drug may have chemopreventive effects that are independent of Cox-2 suppression. 14, 16 Despite the encouraging results of celecoxib for tumor suppression, such use of the drug has been associated with serious problems such as increased risk of cardiovascular death, myocardial infarction, stroke or heart failure, 19, 20 which contraindicate its use as an anticancer agent.
Gene therapy holds great promise as a treatment for bladder cancer, with the use of adenoviral vectors becoming prominent in clinical trials. As examples, adenovirus has been used to treat bladder carcinoma via the delivery of p53 genes in clinical trials in both the United States and Europe, 21, 22 and more recently has been used in a Phase I/IIa trial to deliver genes encoding the CD40 ligand for immunostimulation. 23 Previous work from our laboratory has utilized expression-targeted gene therapy to treat bladder carcinomas via the directed induction of apoptosis through the delivery of caspase genes both in vitro and in vivo. 24, 25 Taking advantage of the fact that bladder carcinomas typically overexpress Cox-2, 24,26 the Cox-2-promoter was used to drive the expression of a combination of caspases 3 and 9, with posttranslational activation, to an orthotopic murine model of transitional cell carcinoma. This gene therapy method has been used to effectively inhibit tumor growth. 25 Herein, the gene therapy method of using the Cox-2 promoter to drive the expression of delivered caspase genes is compared with BCG and celecoxib treatments, using published protocols, to determine the most effective of the three treatment options. The most successful treatment course was then further examined for longterm efficacy.
Materials and methods
All animal procedures were reviewed by the Tulane University Institutional Animal Care & Use Committee (Animal Welfare Assurance Number A4499-01).
Cells
The murine transitional cell carcinoma cell line MB49 (a kind gift from Anthony Atala, Institute for Regenerative Medicine, Wake Forest University Baptist Medical Center, Winston-Salem, NC) was used for the experiments. The MB49 cells were propagated in Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (Gemini BioProducts, West Sacramento, CA), 100 unit per ml penicillin and 100 unit per ml streptomycin (Invitrogen). The cell line was maintained in a humidified cell culture incubator at 37 1C and 5% CO 2 , with media changes occurring every 3 to 4 days.
Setup of murine tumor model
The mice used were immunocompetent female C57/Bl6 (The Jackson Laboratory, Bar Harbor, ME). The creation of mouse bladder tumor defects followed the procedure described in detail in the previous work. 25 Briefly, following anesthesia by inhalation of isoflurane, the backs of all mice were shaved and coated with electroconduction gel. Each bladder was drained via transurethral catheterization (24-gauge catheter), after which a platinum wire was inserted through the catheter and into the bladder lumen. The exterior portion of the wire was tapped, repositioned and tapped again with a Bovie electrocautery unit (Bovie Medical Corporation, St Petersburg, FL) set to deliver 2.5 W of current into the bladder. After the burn injuries were created, the wire and catheter were removed and the animal was cleaned and placed on a heating pad to assist in the maintenance of body temperature. A suspension of 10 5 murine transitional cell carcinoma (TCC) cells (MB49) was then instilled into the bladder through separate transurethral catheterization. The catheter was blocked for 90 min to allow for cellular attachment to the (dorsal) bladder burn sites.
Formation of complexes for gene delivery
The polycation poly (ethylenimine) (PEI), with a reported weight-average molecular weight of 25 kDa (Sigma-Aldrich, St Louis, MO. Cat no. 40872-7), was used as the gene delivery vehicle. The detailed procedure for the formation of transfection complexes is described elsewhere. 25 In short, for each dose of gene delivery complexes,1.8 mg of plasmids coding for Cox-2-driven inducible caspase (iCasp) 3, in 0.9% NaCl and having a total volume of 25 ml, were complexed with 25 ml of PEI stock solution (pH 7) to yield a 7.5:1 PEI nitrogen to DNA phosphate ratio. This 50 ml solution was then combined with 50 ml of solution containing transfection complexes made in the same way, except that plasmids coding for Cox-2-driven iCasp9 were used. Several such 100 ml dosages were prepared at a time in a biological cell culture safety cabinet to preserve sterility, and then were transported at room temperature to the surgical suite for administration into mice.
Transfection treatment procedure and schedule Beginning on the seventh day after instillation of the MB49 cells, transfections were carried out and repeated every 3 days for a total of five treatments in the following manner: following anesthesia with isoflurane, each mouse received urethral catheterization to empty the bladder followed by the intravesical delivery of 100 ml of transfection complexes (or normal saline in the case of negative controls). The transfection solution remained in the bladder for 2 hours, after which the catheter was removed and the bladder was allowed to drain naturally.
The protein products of the delivered genes were exogenously inducible forms of caspases 3 and 9. To activate these proteins, a solution of the homodimerizer AP20187 (ARIAD, Cambridge, MA) was delivered intraperitoneally via a 100 ml bolus. The 100 ml activator solution consisted of AP20187 (2 mg kg À1 ) in a dosing solution of 0.4 mg ml
À1
. For reference, to make 1 ml of dosing solution, 40 ml of 10 mg ml À1 AP20187 would be added to 100 ml poly (ethylene glycol) (PEG 400), vortexed and then 860 ml 2% Tween 20 would be added and the solution vortexed again. The activator was delivered every day, beginning on the day after the first transfection and ending the day before mice were killed. Killing was carried out on the third day after the fifth transfection (16 days after the initial transfection).
The protocol for the long-term study was the same as above, except that the mice were not killed on the third day after the last treatment but rather were left to their normal routines until they became lethargic, cachectic or lost 20% of their original body weight, at which time they were killed. Lethargy was the typical reason for killing.
Celecoxib treatment
Celecoxib (Celebrex, Pfizer) was administrated to mice by one of two different means: locally via bladder lavage or systemically via oral administration. Celecoxib lavage was performed intravesically in a manner similar to the administration of transfection solutions described above. A 100 mg ml À1 stock solution of celecoxib was prepared in DMSO and stored at À20 1C. For one dose, immediately before treatment, 2 ml of this stock solution was mixed with 98 ml of sterile 0.9% saline and vortexed vigorously to yield a 100 ml solution containing 0.2 mg of celecoxib. The quantities were determined based upon a therapeutic dose of 10 mg kg À1 of celecoxib, 27 mouse weights of 20 g and a desired volume of 100 ml based on bladder capacities of B150 ml. 24 Lavages were performed every 3 days for 2 hours each, to match the treatment conditions used for gene delivery.
Systemic celecoxib was administered orally through the diet. Capsules were broken apart and supplemented into mice powder diet 2016 (Harlan Teklad Animal Diets & Bedding, Madison, WI) at a concentration of 1500 p.p.m. This method of dietary preparation has been used successfully in murine cancer models in previous studies and the dosage was based on the recommended human dose of celecoxib. 28, 29 The mice were instilled with tumor cells and tumor tissue was allowed to develop for 7 days before treatment. Mice receiving celecoxib treatments were divided into two groups. One group received the celecoxib-supplemented diet ad libitum for 7 days, after which the celecoxib-supplemented diet was replaced by the regular diet. The second group received the celecoxib treatment for 15 days. Control groups included mice receiving tumor cells but without any treatment, mice without tumor cells but with celecoxib treatment and mice receiving neither tumor cells nor treatment. Killing for all groups was carried out on the twenty-second day following tumor cell (or sham) instillation.
BCG treatment BCG, in the form of TICE BCG, was graciously supplied by Organon Teknika Corporation, Durham, NC. Dosages were supplied as freeze-dried cultures in glass vials, each containing 1-8 Â 10 8 colony-forming units. Each dose, containing 1-8 Â 10 7 colony-forming units diluted with 0.9% saline in a total volume of 100 ml, 30 was delivered intravesically and was allowed to remain in the bladder for 2 hours. Mice were treated weekly for an intended total of six BCG treatments per animal, which is consistent with established clinical protocol. 3 The first treatment was delivered upon ultrasound verification of tumor-like masses within bladder lumena, consistent with the procedure described above for the gene therapy treatments.
Statistics
Groups of data were analyzed by single-factor analysis of variance. For pairwise comparisons, the F-test was used to determine whether a given pair of population variances was equal (ao0.05). This information was then used in designating the appropriate t-tests (typically heteroscedastic) to perform for comparing the means of population pairs. Significantly different pairs were defined as having Po0.05.
Results

Lavage
Upon necropsy, it was found that bladders having undergone transfection with a combination of genes coding for iCasp3 and iCasp9, followed by post-translational activation of both gene products, appeared similar to tumor-free bladders receiving sham treatments: they were translucent, had lumenal capacities of B150 ml and had discrete extralumenal vascularization (Figure 1) . Moreover, statistical analyses showed that there were no significant differences between the masses of wild-type bladders and tumor-inoculated bladders that received the full gene delivery regimen. These results are consistent with our previously published reports. 25, 31 The aim of these investigations was to compare the described gene delivery regimen to existing anti-cancer treatments to further evaluate its efficacy. BCG therapy and celecoxib administration were selected for comparison, and intravesical lavage was chosen for each of these Figure 1 Representative photographs of normal mouse bladder and bladders on day 22 following tumor instillation for: intravesicular gene delivery, dietary celecoxib treatments and untreated controls. Two photographs are shown for mice receiving celecoxib for 7 days, with arrows pointing out areas of relatively avascular tumor growth.
Comparative evaluation of TCC treatments X Zhang and WT Godbey methods to match the mode of administration of the gene delivery complexes. BCG immunotherapy was chosen because it is currently the gold standard for first-line in situ treatment of transitional cell carcinoma. 1 Celecoxib was chosen because of its documented anti-proliferative effects. 5, 11, 16, 17 The results of these anti-cancer treatments upon tumor mass at 22 days post-innoculation are shown in Figure 2 . Tumor weights were calculated as the total bladder mass minus the average mass of wildtype bladders (wild-type data not shown). As the figure reveals, neither the BCG nor the celecoxib treatments yielded significant inhibition of tumor growth as compared with untreated, tumor-inoculated bladders (analysis of variance, nX7, P ¼ 0.40). The appearance of bladders treated via lavage with BCG or celecoxib was similar to control bladders from tumor-inoculated mice that received no treatment: the bladders were significantly larger in overall size, had greater mass, were distinctly red from angiogenesis and had greatly reduced lumenal volumes (data not shown). The bladders treated with BCG or celecoxib lavage had tumor weights of 392.8 ± 187 mg and 340.9 ± 180.8 mg, respectively, as opposed to 3.6±7.7 mg in bladders treated with the gene therapy method. analysis of variance indicated that there was a significant difference in the mean tumor weights that resulted from the three different lavage treatment regimens (nX4, Po0.01). t-Test comparison of tumor weights recorded following the conclusion of gene therapy versus celecoxib lavage trials indicated that the gene delivery method yields significantly lower mean tumor weights (nX4, Po0.01).
Systemic drug delivery
The ineffectiveness of the celecoxib treatment in Figure 2 was questioned. Although delivering the drug via lavage was consistent with the method of administration for the BCG and gene delivery treatments, such administration was inconsistent with the usual oral route of delivery used in clinics and homes. Further investigations of celecoxib, using a more systemic delivery approach, were undertaken. It was found that constant availablity of the drug through the diet was more effective in restricting bladder tumor growth than were celecoxib lavages ( Figure 3) . In designing the experiment, celecoxib administration for 7 days was chosen because the number was similar to the five transfections used in the gene therapy regimen, and celecoxib administration for 15 days was chosen because the time span is identical to the span of time used for the five gene delivery treatments. Although a difference between the mean tumor weights resulting from the three celecoxib treatment methods was noted (analysis of variance, nX6, Po0.001), there was no significant difference noted between the two dietary modes of administration (t-test, nX6, P ¼ 0.23; Figure 3 ). However, mice treated with dietary celecoxib for 15 days had bladders that appeared very similar to normal bladders, whereas mice treated with dietary celecoxib for 7 days had bladders that contained visible tumor masses, which were nodular and white (Figure 1 ). The 15-day administration of celecoxib via the diet was therefore deemed to be preferable to the other two courses of celecoxib treatment examined for the purposes of further investigation (see below).
Although the presence of glycosaminoglycans (GAGs) and uroplakins on the lumenal surface of the bladder could account for the poor efficacy observed for celecoxib lavage, these molecular barriers did not prevent transfection using cationic PEI/DNA gene delivery complexes. Figure 4 shows that local delivery of such complexes to a normal murine bladder is sufficient for successful transfection. Note that this particular experiment utilized only one transfection event, without the use of expression targeting, so subsequent administration of AP20187 was not needed. Because of the number of cells expressing the Figure 2 Tumor masses following various lavage treatment regimens. No difference of mean tumor mass was seen between untreated, BCG-treated or celecoxib-treated bladders (analysis of variance (ANOVA), nX7, P ¼ 0.40). Tumor mass in bladders receiving expression-targeted gene delivery complexes, utilizing Cox-2-driven expression of iCasp3 and iCasp9, was significantly lower than the next-lowest average, celecoxib lavage (t-test, nX4, ***Po0.01). Figure 3 Tumor masses following various courses of celecoxib treatment. There was a difference between the mean tumor weights resulting from the three celecoxib treatment methods (ANOVA, nX6, Po0.001). However, the difference between the mean tumor masses resulting from 7-or 15-day oral administration of the drug was not significant (t-test, nX6, P ¼ 0.23). Both the courses of therapy involving dietary drug administration yielded tumor masses that were significantly lower than those in celecoxib-lavage-treated bladders (nX6). *Po0.05; ***Po0.01.
Comparative evaluation of TCC treatments X Zhang and WT Godbey delivered reporter gene at 3 days post transfection, systemic delivery of the gene delivery complexes was deemed unnecessary.
Celecoxib (diet) versus gene therapy treatment
Although the initial aim of the Cox-2-driven production of caspases 3 and 9 was to bring about apoptosis of carcinoma cells, a positive side effect was easily noted upon necropsy: there was a remarkable reduction in angiogenesis in the treated bladders, as was evident from the colors of the treated versus untreated bladders (Figure 1) . A trial was conducted to compare the effect of this gene therapy system, which works via induction of tumor cell apoptosis as well as antiangiogenesis, against celecoxib, a Cox-2 inhibitor known to suppress angiogenesis. Although 2 weeks of celecoxib administration via the diet produced excellent tumor suppression, the tumor weights in this treatment group were significantly higher than the group receiving the five gene therapy treatments of expression-targeted plasmids encoding iCasp3 and iCasp9 (t-test, nX4, Po0.025; Figure 5 ).
Long-term efficacy of the expression-targeted gene therapy method
The mass of the bladders and any tumor contents were assessed with respect to days post inoculation. An exponential curve was fit to data corresponding to tumor mass within bladders having received sham treatments, to establish a baseline for comparison (R 2 ¼ 0.8603; Figure 6 ). Bladders from mice having been on the gene therapy regimen are included in the figure, which includes bladders from the long-term investigation as well as bladders from other studies. Bladders from very early studies, for which mice died owing to operator error, are included to help establish the trend of tumor growth from early time points. As can be seen in Figure 6 , the masses of tumors within the treated bladders were all below the control curve, and readings could be taken well beyond 30 days (the longest time of survival for an untreated mouse). Data taken exclusively from long-term experiments are shown in Figure 7 .
Discussion
Previous work has demonstrated the anti-tumor effects of the gene therapy system whereby plasmids coding for iCasp3 and iCasp9 under the control of the Cox-2- Comparative evaluation of TCC treatments X Zhang and WT Godbey promoter, with post-translational activation of the gene products, are delivered in an orthotopic murine model of transitional cell carcinoma. 25 Because of those encouraging results, a comparison to existing treatment modalities was warranted. The investigations described here originally sought to compare the gene delivery system to two other forms of lavage treatment for bladder carcinoma: the delivery of BCG, as is currently used in clinical settings, and the delivery of celecoxib. The results obtained led to further investigation onto carcinoma treatment via orally administered celecoxib.
Ever since its efficacy was first demonstrated by Morales et al. 32 in 1976, BCG has remained the treatment of choice for superficial bladder transitional cell carcinoma, and its application has been well documented and accepted. 33, 34 Despite over 30 years of clinical use and extensive studies aimed at trying to understand the working mechanism of BCG as an anti-tumor modality, the exact mechanism of BCG in cancer treatment remains unclear. It has been proposed that there is a two-phase process for BCG action: an initiation phase and an immune-effector phase. 35 In the initiation phase, BCG attaches to the bladder epithelium by a fibronectindependent process, 36, 37 and is subsequently phagocytosed by macrophages, bladder epithelial cells and tumor cells. 38, 39 The bacteria are then processed and presented for immune recognition. During the effector phase, numerous cellular components of the immune system are activated, such as macrophages, natural killer cells, B cells and T cells. The cytokines released by these immune cells might augment the immune responses and hence aid in destruction of the bladder tumor. 40, 41 Celecoxib is a member of a class of inhibitory drugs that specifically target Cox-2, an inducible inflammatory intermediate, as opposed to the constitutively expressed Cox-1 enzyme. The drug was designed to exploit the subtle structural differences between the active sites of the Cox isoenzymes. 42 Overexpression of Cox-2 has been shown to correlate with the development of tumor tissues through several mechanisms, 43 including angiogenesis. Induction of angiogenesis is thought to come about through increased production of prostaglandins and other proangiogenic factors such as vascular endothelial growth factor. 43, 44 Celecoxib has been shown to prevent tumor growth and development through suppression of angiogenesis in various carcinomas, including those of the prostate 29 and breast. 27 The data presented in Figure 2 indicate that lavage administration of neither BCG nor celecoxib had a significant effect upon final tumor weights in the current orthotopic model of transitional cell carcinoma. Drug absorbance in the bladder through intravesical delivery is affected by the physiochemical properties of the drug itself and also by the integrity of the bladder urothelium. 1 Besides the uroplakins-rigid plaques covering the round surfaces of apical cells-the mucin layer, which overlies the uroplakins and is composed of GAGs, further augments the strength of the permeability barrier, which acts by physically blocking instilled drug molecules from reaching the underlying tight junctions and cell membrane. 45 It is possible that the layers of uroplakins and mucin acted to prevent the absorbance of celecoxib, greatly reducing its therapeutic effects.
BCG adherence to the bladder wall involves both specific and non-specific interactions. As mentioned above, the bladder wall is covered with a hydrophilic GAG layer. Both the GAG layer and BCG cell wall are highly negatively charged, which could, in theory, lead to BCG accumulation on the bladder wall at close docking distance. 46, 47 Moreover, the electrostatically repellent force between the GAGs and BCG may lead to irreversible adherence of BCG to the bladder wall. 46 Besides the non-specific interactions, BCG adherence seems also to be mediated by binding between BCG and fibronectin. 46 As Ratliff et al. 48 observed in their murine model, electrocautery damage of the bladder wall seemed to lower the negative charges of the GAG layer, which made it easier for BCG docking and adherence. BCG absorbance in the bladder would therefore not have been a limiting factor in the present model, and it was predicted that BCG would have a positive therapeutic effect. The prediction, however, was not borne out by the data, perhaps because we implanted a greater number of tumor cells in our murine model than in reports of BCG effectiveness in murine models (1 Â 10 5 versus 1 Â 10 4 cells per mouse), and the treatments here were carried out on developed tumors (commencing 7 days after tumor inoculation, as opposed to 24 hours after cell implantation). 30, 49 The exact mechanism of how the PEI/DNA gene delivery complexes traversed the bladder permeability barrier is not presently clear. However, it is likely that there was interaction between the highly negatively charged GAG layer 46 and the positively charged PEI/ DNA complexes, 50 which may have greatly facilitated the capture of the gene delivery complexes from the solution contained within the bladder. Moreover, the high surface to volume ratio of the PEI nanoparticles may have also had a role in the transvesical absorption of encapsulated gene delivery complexes. 45 The destruction of GAG and uroplakin layers through electrocautery can be eliminated as reasons for successful gene delivery. Figure 4 demonstrates that unmodified PEI/DNA complexes can successfully transfect intact murine bladder. 
Comparative evaluation of TCC treatments X Zhang and WT Godbey
The results shown in Figure 3 demonstrate that although continuously available celecoxib, administrated through the diet for 15 days, could effectively inhibit the tumor growth, its therapeutic effect was less efficient than the five discrete gene therapy treatments of expression-targeted plasmids encoding iCasp3 and iCasp9 administered over 15 days. This indicates that either the anti-angiogenic effects of the gene therapy treatments were more successful at preventing tumor growth than were the celecoxib treatments, or that the pro-apoptotic consequences of the gene delivery system were involved in addition to anti-angiogenesis. In light of our previous work that demonstrated that tumor cells were indeed dying from apoptosis brought about by the expression of delivered genes coding for iCasp3 and iCasp9 31 , it is reasonable to assert that the expression-targeted gene therapy system operates via a mechanism that is different from that of celecoxib.
The experiments presented here have shown that the delivery of genes coding for iCasp3 and iCasp9 under the control of the Cox-2-promoter, with post-translational activation of the gene products, has significant therapeutic benefits in an orthotopic murine model of transitional cell carcinoma. Compared with the treatment methods utilizing BCG or celecoxib, the expression-targeted gene therapy method demonstrated significantly stronger inhibition of tumor progression when drug delivery was via lavage. Intravesical delivery of the gene delivery complexes was also more effective in preventing tumor development than was orally administered celecoxib. Data from Figure 6 suggested that the gene delivery treatment could effectively inhibit tumor growth, and long-term data indicated that life expectancy was extended. With further optimization of delivery vector choice and treatment schedule, the gene therapy method will be very promising for further clinical investigation.
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